Nurix Therapeutics NRIX 深 沪
已收盘 08-21 16:00:00 美东时间
26.72
-0.330
-1.22%
华盛通- 最 高27.50
- 今 开27.41
- 成交量 148.59万股
- 最 低 26.70
- 昨 收 27.05
- 总市值 27.73亿
- 52周最高 28.23
- 市盈率 静 --
- 换手率 1.43%
- 52周最低 8.195
- 委 比 -23.86%
- 总股本 1.04亿
- 历史最高 52.38
- 量 比 1.26
- 振 幅 2.96%
- 历史最低 4.22
- 每 手 1
- 风险率 4.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Wes Burwell has joined Nurix Therapeutics as Chief Human Resources Officer, bringing over 20 years of leadership experience in scaling organizations through clinical development and commercialization. He will lead Nurix's human resources team as the company advances its late-stage clinical pipeline and prepares for commercialization. Burwell previously served as vice president of human resources at Bolt Biotherapeutics and held senior HR roles at...
08-20 11:00
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, ...
08-04 19:14
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nurix Therapeutics and Roche have initiated a global Phase 3 trial, DAYBreak CLL-306, to compare bexobrutideg, a BTK degrader, with pirtobrutinib in relapsed/refractory CLL/SLL patients who previously received covalent BTK inhibitors. The study aims to demonstrate bexobrutideg's superiority, with primary endpoints of ORR and PFS. This marks the first Phase 3 trial for bexobrutideg, targeting a new treatment approach for CLL.
08-04 05:00
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31
UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.
07-23 02:45
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics has entered a global collaboration with Roche to co-develop and commercialize bexobrutideg, a targeted protein degradation medicine. Under the agreement, Nurix receives $700 million upfront, with potential milestone payments up to $2.3 billion. Development costs are split 40% by Nurix and 60% by Roche. Both companies will share U.S. profits and losses, while Roche handles commercialization outside the U.S., paying Nurix royalti...
07-21 20:01
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
美股大行评级 | 潜在涨幅98.68%！DA Davidson上调Almonty Industries目标价至33美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持Almonty Industries"买入"评级，目标价从25美元升至33美元；Stifel：维持Nurix Therapeutics"买入"评级，目标价从34美元升至40美元
07-13 10:13
